CTOs on the Move

Imara

www.imaratx.com

 
Imara Inc. is dedicated to developing novel therapeutics for people living with sickle cell disease and other hemoglobinopathies. Sickle cell disease is a rare, genetic blood disease that causes red blood cells to sickle and become damaged, activating immune cells and blocking blood flow in capillaries, injuring many organs and causing daily pain. Imara is developing IMR-687, a highly selective, potent small molecule inhibitor of phosphodiesterase-9 (PDE9i), to treat patients with sickle cell disease. Imara was launched following an 18-month scientific collaboration between orphan drug accelerator Cydan Development and H. Lundbeck A/S.
  • Number of Employees: 0-25
  • Annual Revenue: $0-1 Million
  • www.imaratx.com
  • 116 Huntington Avenue 6th Floor
    Boston, MA USA 02116
  • Phone: 617.206.2020

Executives

Name Title Contact Details

Funding

Imara raised $63M on 03/18/2019

Similar Companies

Regenacy Pharmaceuticals

Regenacy Pharmaceuticals is developing a novel, disease-modifying approach to treating peripheral neuropathies that goes beyond pain and symptom management to restore peripheral nerve function.

Octave Bioscience

Octave is developing a comprehensive, first-in-class Care Management Platform.

M3 Biotechnology

M3 is a biopharmaceutical company focused on development of therapeutics to address Alzheimer`s, Parkinson`s and Neurodegeneration.

HomeDNA

HomeDNA, Inc. is a Keller, TX-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

BioLife Solutions

BioLife Solutions is a leading supplier of cell and gene therapy bioproduction tools.